ADMA Biologics, Inc. (ADMA)
12.73
-0.48
(-3.63%)
USD |
NASDAQ |
Nov 06, 16:00
12.74
+0.01
(+0.08%)
After-Hours: 20:00
ADMA Biologics Research and Development Expense (Annual) : 4.762M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 4.762M |
| December 31, 2024 | 1.813M |
| December 31, 2023 | 3.30M |
| December 31, 2022 | 3.825M |
| December 31, 2021 | 3.886M |
| December 31, 2020 | 5.907M |
| December 31, 2019 | 2.344M |
| December 31, 2018 | 3.926M |
| Date | Value |
|---|---|
| December 31, 2017 | 6.230M |
| December 31, 2016 | 7.688M |
| December 31, 2015 | 7.016M |
| December 31, 2014 | 9.517M |
| December 31, 2013 | 9.303M |
| December 31, 2012 | 3.469M |
| December 31, 2011 | 0.00 |
| December 31, 2010 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Nektar Therapeutics | 117.07M |
| Rhythm Pharmaceuticals, Inc. | 166.90M |
| Arcutis Biotherapeutics, Inc. | 77.05M |